| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | 0% | $32,867,152 | +$9,371,621 | 1,939,065 | +40% | RA Capital Management, L.P. | 31 Dec 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 10% | 0% | $32,277,156 | +$7,561,497 | 1,904,257 | +31% | BVF PARTNERS L P/IL | 31 Dec 2025 |
| Nantahala Capital Management, LLC | 9.4% | +12% | $15,696,850 | +$4,257,850 | 1,235,000 | +37% | Nantahala Capital Management, LLC | 30 Sep 2025 |
| ORBIMED ADVISORS LLC | 6.4% | -28% | $20,124,735 | +$3,734,085 | 1,187,300 | +23% | OrbiMed Advisors LLC | 31 Dec 2025 |
| Affinity Asset Advisors, LLC | 5.7% | -24% | $19,087,141 | +$814,240 | 1,051,054 | +4.5% | Affinity Asset Advisors, LLC | 22 Jan 2026 |
| MILLENNIUM MANAGEMENT LLC | 5% | +4% | $14,726,601 | +$743,163 | 934,429 | +5.3% | Millennium Management LLC | 17 Feb 2026 |
| Caligan Partners LP | 4.9% | -23% | $14,941,984 | +$816,990 | 881,533 | +5.8% | Caligan Partners LP | 31 Dec 2025 |
| VANGUARD GROUP INC | 4.4% | -17% | $14,602,165 | +$2,023,878 | 804,084 | +16% | The Vanguard Group | 31 Dec 2025 |
| Ikarian Capital, LLC | 3.8% | -62% | $9,049,101 | -$6,100,673 | 711,967 | -40% | Ikarian Capital, LLC | 30 Sep 2025 |
| Point72 Asset Management, L.P. | 3.5% | -56% | $10,636,159 | -$7,228,853 | 627,502 | -40% | Point72 Asset Management, L.P. | 31 Dec 2025 |
| Crutcher Patrick J | 4.2% | $3,593,514 | 549,467 | Patrick J. Crutcher | 06 Aug 2025 | |||
| SILVERARC CAPITAL MANAGEMENT, LLC | 2.8% | -53% | $8,889,190 | -$3,330,438 | 524,436 | -27% | SilverArc Capital Management, LLC | 31 Dec 2025 |
| BALYASNY ASSET MANAGEMENT L.P. | 2.4% | -63% | $7,446,338 | -$6,409,202 | 439,312 | -46% | Balyasny Asset Management L.P. | 31 Dec 2025 |
As of 31 Dec 2025, 84 institutional investors reported holding 19,885,517 shares of Avalo Therapeutics, Inc. - Common Stock, par value $0.001 per share (AVTX). This represents 106% of the company’s total 18,688,580 outstanding shares.
The largest institutional shareholders of Avalo Therapeutics, Inc. - Common Stock, par value $0.001 per share (AVTX) together control 82% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BVF INC/IL | 7.3% | 1,355,257 | +0% | 0.83% | $24,611,467 |
| Nantahala Capital Management, LLC | 6.6% | 1,235,000 | 0% | 1.3% | $22,427,600 |
| ORBIMED ADVISORS LLC | 6.4% | 1,187,300 | -12% | 0.46% | $21,561,368 |
| Affinity Asset Advisors, LLC | 5.6% | 1,051,054 | +4.5% | 1.4% | $19,087,141 |
| Caligan Partners LP | 4.7% | 881,533 | +5.8% | 1.5% | $16,008,639 |
| VANGUARD GROUP INC | 4.3% | 804,084 | +16% | 0% | $14,602,165 |
| RA CAPITAL MANAGEMENT, L.P. | 3.5% | 662,968 | 0% | 0.12% | $12,039,499 |
| MILLENNIUM MANAGEMENT LLC | 3.5% | 659,979 | +380% | 0.01% | $11,985,219 |
| Point72 Asset Management, L.P. | 3.4% | 627,502 | -40% | 0.02% | $11,395,436 |
| BANK OF AMERICA CORP /DE/ | 3.3% | 621,350 | +2.6% | 0% | $11,283,716 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.9% | 550,000 | +113% | 0.02% | $9,988,000 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 2.8% | 524,436 | -27% | 1.4% | $9,523,758 |
| MARSHALL WACE, LLP | 2.7% | 507,550 | +806% | 0.01% | $9,217,107 |
| TCG Crossover Management, LLC | 2.6% | 483,000 | 0% | 0.29% | $8,771,280 |
| Commodore Capital LP | 2.6% | 483,000 | 0% | 0.58% | $8,771,280 |
| UBS Group AG | 2.6% | 477,816 | +957% | 0% | $8,677,138 |
| JENNISON ASSOCIATES LLC | 2.5% | 475,625 | 0.01% | $8,637,350 | |
| Soleus Capital Management, L.P. | 2.4% | 441,978 | 0.34% | $8,026,320 | |
| Balyasny Asset Management L.P. | 2.4% | 439,312 | -46% | 0.01% | $7,977,906 |
| CITADEL ADVISORS LLC | 2.2% | 419,491 | -13% | 0.01% | $7,617,957 |
| Patient Square Capital LP | 1.7% | 311,966 | +212% | 1.2% | $5,665,303 |
| BlackRock, Inc. | 1.5% | 289,571 | +88% | 0% | $5,258,610 |
| Boxer Capital Management, LLC | 1.5% | 275,000 | +120% | 1.1% | $4,994,000 |
| MORGAN STANLEY | 1.4% | 264,907 | +2648970% | 0% | $4,810,711 |
| Velan Capital Investment Management LP | 1.4% | 263,642 | 0% | 2.8% | $4,787,739 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 19,885,517 | $361,121,251 | +$79,863,888 | $18.16 | 84 |
| 2025 Q3 | 15,317,685 | $194,685,792 | +$95,069,684 | $12.71 | 65 |
| 2025 Q2 | 7,843,040 | $39,137,186 | -$2,087,558 | $4.99 | 35 |
| 2025 Q1 | 8,255,057 | $66,123,710 | +$5,779,142 | $8.01 | 33 |
| 2024 Q4 | 7,530,521 | $55,951,612 | +$4,829,815 | $7.43 | 33 |
| 2024 Q3 | 6,656,933 | $63,199,568 | +$55,874,127 | $9.50 | 28 |
| 2024 Q2 | 771,102 | $9,615,066 | +$8,430,049 | $12.47 | 21 |
| 2024 Q1 | 87,507 | $1,897,924 | +$1,405,693 | $21.75 | 18 |
| 2023 Q4 | 22,966 | $209,366 | +$209,366 | $9.00 | 12 |